Program
hafnium oxide
Also written as “JNJ-90301900”, “PEP503” and “JNJ-90301900 (NBTXR3)”.
Its studies are mostly in Squamous Cell Carcinoma of Head and Neck · Carcinoma, Non-Small-Cell Lung · Rectal Neoplasms, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 33 open or running | phase 3since May 4, 2021 | May 4, 2021 | Jun 30, 2028phase 3 · NCT04892173 |
| PharmaEngine | 20 open or running | phase 2since Jun 1, 2015 | Jun 1, 2015 | none ahead |
| Nanobiotix | 11 open or running | phase 1since Apr 10, 2018 | Apr 10, 2018 | Apr 30, 2027phase 1 · NCT03589339 |
- Named in Johnson & Johnson’s own pipeline as
JNJ-1900 (NBTXR3)
, phase 3, as of Oct 13, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 1, 2015First study: phase 2 study in Rectal NeoplasmsNew to PharmaEnginePharmaEngine · NCT02465593 · 32 enrolled · Taiwan
- Aug 31, 2016Phase 2 study in Squamous Cell Carcinoma of Head and NeckPharmaEngine · NCT02901483 · 12 enrolled · Taiwan
- Apr 10, 2018Nanobiotix's first study: phase 1 study in Squamous Cell Carcinoma of Head and NeckNew to NanobiotixNanobiotix · NCT03589339 · 145 enrolled · United States
- May 4, 2021Johnson & Johnson's first study: phase 3 study in Carcinoma, Squamous CellNew to Johnson & JohnsonJohnson & Johnson · NCT04892173 · 500 planned · United States, Austria, Belgium and more
- Oct 30, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT06667908 · 130 planned · United States, Australia, Brazil and more
- Oct 17, 2025Phase 1 study in Squamous Cell Carcinoma of Head and NeckJohnson & Johnson · NCT07219212 · 45 planned · United States, France, Japan and more
Ahead
- Apr 30, 2027Primary completion: phase 1 study in Squamous Cell Carcinoma of Head and NeckNanobiotix · NCT03589339
- Jun 30, 2028Primary completion: phase 3 study in Carcinoma, Squamous CellJohnson & Johnson · NCT04892173
- Jul 14, 2028Primary completion: phase 1 study in Squamous Cell Carcinoma of Head and NeckJohnson & Johnson · NCT07219212
- Dec 31, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT06667908
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07219212Squamous Cell Carcinoma of Head and Neck · United States, France, Japan and more | 1 | Recruiting | Johnson & Johnson | Jul 14, 2028 | 45 |
| NCT06667908Carcinoma, Non-Small-Cell Lung · United States, Australia, Brazil and more | 2 | Recruiting | Johnson & Johnson | Dec 31, 2028 | 130 |
| NCT04892173Carcinoma, Squamous Cell · United States, Austria, Belgium and more | 3 | Recruiting | Johnson & Johnson | Jun 30, 2028 | 500 |
| NCT03589339Squamous Cell Carcinoma of Head and Neck · United States | 1 | Active, not recruiting | Nanobiotix | Apr 30, 2027 | 145 |
| NCT02901483Squamous Cell Carcinoma of Head and Neck · Taiwan | 2 | Terminated | PharmaEngine | Aug 17, 2020 | 12 |
| NCT02465593Rectal Neoplasms · Taiwan | 2 | Terminated | PharmaEngine | Jul 28, 2021 | 32 |
How it is read
Names in the registry
- “JNJ-90301900”, 2 entries
- “PEP503”, 2 entries
- “JNJ-90301900 (NBTXR3)”, 1 entry
- “NBTXR3”, 1 entry
Conditions, from the studies’ own filings
- Squamous Cell Carcinoma of Head and Neck, 4 studies
- Carcinoma, Non-Small-Cell Lung, 1 study
- Rectal Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.